Supplementary Material

Synthesis of 3-substituted pyrrolidin-2-ones and 3-substituted piperidin-2-ones from esters

Lara Brunotte, Lars Beckmann, Marko Ljiljanic, and Till Opatz*

Department of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10–14, 55128 Mainz, Germany E-mail: opatz@uni-mainz.de

Table of Contents



Figure 2: ¹³C-NMR (75 MHz, CDCl₃) of 2-azidoethan-1-ol (22).



Figure 3: ¹H-NMR (300 MHz, CDCl₃) of 3-azidopropan-1-ol (23).



220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 f1 (ppm)

Figure 4: ¹³C-NMR (75 MHz, CDCl₃) of 3-azidopropan-1-ol (23).



Figure 5: ¹H-NMR (300 MHz, CDCl₃) of 2-azidoethyl trifluoromethanesulfonate **(16)**.



Figure 6: ¹³C-NMR (75 MHz, CDCl₃) of 2-azidoethyl trifluoromethanesulfonate (16).



Figure 7: ¹H-NMR (300 MHz, CDCl₃) of 3-azidopropyl trifluoromethanesulfonate **(17)**.



Figure 8: ¹³C-NMR (75 MHz, CDCl₃) of 3-azidopropyl trifluoromethanesulfonate (17).



Figure 9: ¹H-NMR (300 MHz, CDCl₃) of methyl 4-azido-2-phenylbutanoate (25).



Figure 10: ¹³C-NMR (75 MHz, CDCl₃) of methyl 4-azido-2-phenylbutanoate (25).



Figure 11: ¹H-NMR (300 MHz, CDCl₃) of methyl 5-azido-2-phenylpentanoate **(26)**.



Figure 12: ¹³C-NMR (75 MHz, CDCl₃) of methyl 5-azido-2-phenylpentanoate **(26)**.



Figure 13: ¹H-NMR (300 MHz, CDCl₃) of 3-phenylpyrrolidin-2-one (28).



Figure 14: ¹³C-NMR (75 MHz, CDCl₃) of 3-phenylpyrrolidin-2-one (28).



Figure 15: ¹H-NMR (300 MHz, CDCl₃) of 3-phenylpiperidin-2-one (29).



Figure 16: ¹³C-NMR (75 MHz, CDCl₃) of 3-phenylpiperidin-2-one (29).



Figure 17: ¹H-NMR (300 MHz, CDCl₃) of 3-(*o*-tolyl)pyrrolidin-2-one (30).



Figure 18: ¹³C-NMR (75 MHz, CDCl₃) of 3-(*o*-tolyl)pyrrolidin-2-one (30).



Figure 19: ¹H-NMR (300 MHz, CDCl₃) of 3-(*o*-tolyl)piperidin-2-one (31).



Figure 20: ¹³C-NMR (75 MHz, CDCl₃) of 3-(*o*-tolyl)piperidin-2-one (31).



Figure 21: ¹H-NMR (300 MHz, CDCl₃) of 3-(*p*-tolyl)pyrrolidin-2-one (32).



Figure 22: ¹³C-NMR (75 MHz, CDCl₃) of 3-(*p*-tolyl)pyrrolidin-2-one (32).



Figure 23: ¹H-NMR (300 MHz, CDCl₃) of 3-(*p*-tolyl)piperidin-2-one (33).



Figure 24: ¹³C-NMR (75 MHz, CDCl₃) of 3-(*p*-tolyl)piperidin-2-one **(33)**.



Figure 25: ¹H-NMR (300 MHz, CDCl₃) of 3-(naphthalen-2-yl)pyrrolidin-2-one (34).



Figure 26: ¹³C-NMR (75 MHz, CDCl₃) of 3-(naphthalen-2-yl)pyrrolidin-2-one (34).



Figure 27: ¹H-NMR (300 MHz, CDCl₃) of 3-(naphthalen-2-yl)piperidin-2-one (35).

Figure 28: ¹³C-NMR (75 MHz, CDCl₃) of 3-(naphthalen-2-yl)piperidin-2-one (35).

Figure 29: ¹H-NMR (300 MHz, CDCl₃) of 3,3-diphenylpiperidin-2-one (37).

Figure 30: ¹³C-NMR (75 MHz, CDCl₃) of 3,3-diphenylpiperidin-2-one (37).

Figure 31: ¹H-NMR (300 MHz, CDCl₃) of 3-(2-fluorophenyl)pyrrolidin-2-one (38).

Figure 32: ¹³C-NMR (75 MHz, CDCl₃) of 3-(2-fluorophenyl)pyrrolidin-2-one (38).

Figure 33: ¹H-NMR (300 MHz, CDCl₃) of 3-(2-fluorophenyl)piperidin-2-one (39).

Figure 34: ¹³C-NMR (75 MHz, CDCl₃) of 3-(2-fluorophenyl)piperidin-2-one (39).

Figure 35: ¹H-NMR (300 MHz, CDCl₃) of 3-(4-chlorophenyl)pyrrolidin-2-one (40).

Figure 36: ¹³C-NMR (75 MHz, CDCl₃) of 3-(4-chlorophenyl)pyrrolidin-2-one (40).

Figure 37: ¹H-NMR (400 MHz, CDCl₃) of 3-(4-chlorophenyl)piperidin-2-one (41).

Figure 38: ¹³C-NMR (101 MHz, CDCl₃) of 3-(4-chlorophenyl)piperidin-2-one (41).

Figure 39: ¹H-NMR (300 MHz, CDCl₃) of 3-(3-bromophenyl)pyrrolidin-2-one **(42)**.

Figure 40: ¹³C-NMR (75 MHz, CDCl₃) of 3-(3-bromophenyl)pyrrolidin-2-one **(42)**.

Figure 41: ¹H-NMR (300 MHz, CDCl₃) of 3-(3-bromophenyl)piperidin-2-one (43).

Figure 42: ¹³C-NMR (75 MHz, CDCl₃) of 3-(3-bromophenyl)piperidin-2-one (43).

Figure 43: ¹H-NMR (300 MHz, CDCl₃) of 3-(4-(trifluoromethyl)phenyl)pyrrolidin-2-one (44).

Figure 44: ¹³C-NMR (75 MHz, CDCl₃) of 3-(4-(trifluoromethyl)phenyl)pyrrolidin-2-one (44).

Figure 45: ¹H-NMR (300 MHz, CDCl₃) of 3-(4-(trifluoromethyl)phenyl)piperidin-2-one (45).

Figure 46: ¹³C-NMR (75 MHz, CDCl₃) of 3-(4-(trifluoromethyl)phenyl)piperidin-2-one (45).

Figure 47: ¹H-NMR (300 MHz, CDCl₃) of 3-(4-(methylthio)phenyl)pyrrolidin-2-one (46).

Figure 48: ¹³C-NMR (75 MHz, CDCl₃) of 3-(4-(methylthio)phenyl)pyrrolidin-2-one (46).

Figure 49: ¹H-NMR (300 MHz, CDCl₃) of 3-(4-(methylthio)phenyl)piperidin-2-one (47).

Figure 50: ¹³C-NMR (75 MHz, CDCl₃) of 3-(4-(methylthio)phenyl)piperidin-2-one (47).

Figure 51: ¹H-NMR (300 MHz, CDCl₃) of 3-(3,4-dimethoxyphenyl)pyrrolidin-2-one **(48)**.

Figure 52: ¹³C-NMR (75 MHz, CDCl₃) of 3-(3,4-dimethoxyphenyl)pyrrolidin-2-one (48).

Figure 53: ¹H-NMR (300 MHz, CDCl₃) of 3-(3,4-dimethoxyphenyl)piperidin-2-one **(49)**.

Figure 54: ¹³C-NMR (75 MHz, CDCl₃) of 3-(3,4-dimethoxyphenyl)piperidin-2-one (49).

Figure 55: ¹H-NMR (300 MHz, CDCl₃) of *tert*-butyl 3-(2-oxopyrrolidin-3-yl)-1*H*-indole-1-carboxylate **(50)**.

Figure 56: ¹³C-NMR (75 MHz, CDCl₃) of *tert*-butyl 3-(2-oxopyrrolidin-3-yl)-1*H*-indole-1-carboxylate **(50)**.

Figure 57: ¹H-NMR (300 MHz, CDCl₃) of *tert*-butyl 3-(2-oxopiperidin-3-yl)-1*H*-indole-1-carboxylate **(51)**.

Figure 58: ¹³C-NMR (75 MHz, CDCl₃) of *tert*-butyl 3-(2-oxopiperidin-3-yl)-1*H*-indole-1-carboxylate (51).

Figure 59: ¹H-NMR (300 MHz, CDCl₃) of 3-(4-isobutylphenyl)-3-methylpyrrolidin-2-one (52).

Figure 60: ¹³C-NMR (75 MHz, CDCl₃) of 3-(4-isobutylphenyl)-3-methylpyrrolidin-2-one (52).

Figure 61: ¹H-NMR (300 MHz, CDCl₃) of 3-(4-isobutylphenyl)-3-methylpiperidin-2-one (53).

Figure 62: ¹³C-NMR (75 MHz, CDCl₃) of 3-(4-isobutylphenyl)-3-methylpiperidin-2-one (53).

Figure 63: ¹H-NMR (300 MHz, MeOD-d₄) of 3,3'-(1,4-phenylene)bis(piperidin-2-one) **(54)**.

Figure 64: ¹³C-NMR (75 MHz, MeOD-d₄) of 3,3'-(1,4-phenylene)bis(piperidin-2-one) (54).

Figure 65: ¹H-NMR (300 MHz, MeOD-d₄) of 3,3'-(1,4-phenylene)bis(piperidin-2-one) **(55)**.

Figure 66: ¹³C-NMR (75 MHz, MeOD-d₄) of 3,3'-(1,4-phenylene)bis(piperidin-2-one) (55).

Figure 67: ¹H-NMR (300 MHz, CDCl₃) of 3-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1*H*-indol-3-yl)pyrrolidin-2-one **(56)**.

Figure 68: ¹³C-NMR (75 MHz, CDCl₃) of 3-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1*H*-indol-3-yl)pyrrolidin-2-one **(56)**.

Figure 69: ¹H-NMR (300 MHz, CDCl₃) of 3-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1*H*-indol-3-yl)piperidin-2-one **(57)**.

Figure 70: ¹³C-NMR (75 MHz, CDCl₃) of 3-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)piperidin-2-one **(57)**.

Figure 71: ¹H-NMR (300 MHz, CDCl₃) of 3-cyclohexylpyrrolidin-2-one (58).

Figure 72: ¹³C-NMR (75 MHz, CDCl₃) of 3-cyclohexylpyrrolidin-2-one (58).

Figure 73: ¹H-NMR (300 MHz, CDCl₃) of 3-cyclohexylpiperidin-2-one (59).

Figure 74: ¹³C-NMR (75 MHz, CDCl₃) of 3-cyclohexylpiperidin-2-one (59).

Figure 75: ¹H-NMR (300 MHz, CDCl₃) of 3-octylpyrrolidin-2-one **(60)**.

Figure 76: ¹³C-NMR (75 MHz, CDCl₃) of 3-octylpyrrolidin-2-one (60).

Figure 77: ¹H-NMR (300 MHz, CDCl₃) of 3-octylpiperidin-2-one **(61)**.

Figure 78: ¹³C-NMR (75 MHz, CDCl₃) of 3-octylpiperidin-2-one **(61)**.

Figure 79: ¹H-NMR (300 MHz, CDCl₃) of 3-phenethylpyrrolidin-2-one (62).

Figure 80: ¹³C-NMR (75 MHz, CDCl₃) of 3-phenethylpyrrolidin-2-one (62).

Figure 81: ¹H-NMR (300 MHz, CDCl₃) of 3-phenethylpiperidin-2-one **(63)**.

Figure 82: ¹³C-NMR (75 MHz, CDCl₃) of 3-phenethylpiperidin-2-one (63).